Related Experiment Video
Updated: Jul 7, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Current therapy of lupus nephritis. Which is the best option?
L Silva-Fernández1, J L Andreu-Sánchez, E M Ginzler
1Servicio de Reumatología, Hospital Universitario Puerta de Hierro, Madrid, Spain. lsilvaf.hpth@salud.madrid.org
Abstract:
Renal involvement in systemic lupus erythematosus (SLE) is an important cause of morbidity and mortality, reaching a prevalence of 39% during the course of the disease. Currently, the therapy for severe lupus nephritis is based on the use of high-dose corticosteroids and immunosuppressive drugs, being traditionally cyclophosphamide the most frequently used agent. Recent studies have demonstrated the efficacy of mycophenolate mofetil as induction therapy for lupus nephritis. Azathioprine, a safe drug during pregnancy, has not been demonstrated to be as effective as mycophenolate or cyclophosphamide as induction therapy, although it is an effective drug for maintenance of remission.
More Related Videos
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Kidney Transplant II: Surgical Procedure
